ClinicalTrials.gg

Program

alimatravir

Also written as “MK-8527”, “Alimatravir” and “[14C]MK-8527”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · Renal Insufficiency, led by Merck.

Furthest: phase 3, since Jun 26, 202517 company-led studies, 4 open or runningNext primary completion: Jan 19, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck174 open or runningphase 3since Jun 26, 2025Jul 30, 2018Jan 19, 2027phase 1 · NCT07600775
  • Named in Merck’s own pipeline as alimatravir MK-8527, phase 3, as of Nov 2, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 2 studies since Jul 30, 2018.

  1. Sep 13, 2023Phase 2 study in HIVNCT06045507 · 352 enrolled · United States, Israel, South Africa
  2. Feb 29, 2024Phase 1 study in Renal InsufficiencyNCT06295796 · 18 enrolled · United States
  3. Aug 28, 2024Phase 1 study in HealthyNCT06580587 · 13 enrolled · United States
  4. Jan 14, 2025Phase 1 study in Acquired Immunodeficiency SyndromeNCT06783192 · 14 enrolled · United States
  5. Feb 4, 20252 phase 1 studies in HealthyNCT06816043, NCT06826989
  6. Mar 18, 2025Phase 1 study in HealthyNCT06893081 · 16 enrolled · United States
  7. Jun 9, 2025Phase 1 study in Hepatic ImpairmentNCT07025551 · 18 enrolled · United States
  8. Jun 26, 2025Phase 3 study in Acquired Immunodeficiency SyndromeNCT07044297 · 4,390 enrolled · United States, Argentina, Brazil and more
  9. Jul 3, 2025Phase 1 study in HealthyNCT07063238 · 42 enrolled · United States
  10. Jul 8, 2025Phase 3 study in Acquired Immunodeficiency SyndromeNCT07071623 · 4,580 planned · Kenya, South Africa, Uganda
  11. Apr 7, 2026Phase 1 study in HealthyNCT07528508 · 14 enrolled · United States
  12. May 15, 2026Phase 1 study in Acquired Immunodeficiency SyndromeNCT07600775 · 14 planned
  13. Jun 16, 2026Phase 1 study in HealthyNCT07661108 · 44 enrolled · United States
  14. Sep 23, 2026Phase 2 study in HIVNCT07850609 · 80 planned · United States, Canada

Ahead

  1. Jan 19, 2027Primary completion: phase 1 study in Acquired Immunodeficiency SyndromeNCT07600775
  2. Jul 22, 2027Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07044297
  3. Oct 18, 2027Primary completion: phase 3 study in Acquired Immunodeficiency SyndromeNCT07071623
  4. Dec 2, 2027Primary completion: phase 2 study in HIVNCT07850609

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07850609HIV · United States, Canada2RecruitingDec 2, 202780
NCT07661108Healthy · United States1CompletedOct 28, 202644
NCT07600775Acquired Immunodeficiency Syndrome1Not yet recruitingJan 19, 202714
NCT07528508Healthy · United States1CompletedJul 31, 202614
NCT07071623Acquired Immunodeficiency Syndrome · Kenya, South Africa, Uganda3RecruitingOct 18, 20274,580
NCT07063238Healthy · United States1CompletedDec 6, 202542
NCT07044297Acquired Immunodeficiency Syndrome · United States, Argentina, Brazil and more3Active, not recruitingJul 22, 20274,390
NCT07025551Hepatic Impairment · United States1CompletedFeb 13, 202618
NCT06893081Healthy · United States1CompletedJun 19, 202516
NCT06826989Healthy · United States1CompletedJun 4, 20258
NCT06816043Healthy · United States1CompletedJun 5, 202520
NCT06783192Acquired Immunodeficiency Syndrome · United States1CompletedOct 11, 202314
NCT06580587Healthy · United States1CompletedMar 27, 202613
NCT06295796Renal Insufficiency · United States1CompletedJan 31, 202518
NCT06045507HIV · United States, Israel, South Africa2CompletedDec 12, 2024352
NCT05494736Acquired Immunodeficiency Syndrome · Romania, South Africa1CompletedJan 31, 202420
NCT03615183Acquired Immunodeficiency Syndrome · Romania1CompletedSep 26, 201917

How it is read

Names in the registry

  • “MK-8527”, 15 entries
  • “Alimatravir”, 1 entry
  • “[14C]MK-8527”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.